Status:

COMPLETED

A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome

Lead Sponsor:

Dr Alexander McIntyre Inc.

Conditions:

Major Depression

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

To compare the efficacy of Quetiapine SR versus placebo over 8 weeks in unipolar non-psychotic adult outpatients depression and comorbid fibromyalgia. This will be measured by the last observation car...

Detailed Description

Secondary Endpoints include * Change from baseline to week 8 in Brief Pain Inventory (short form) total score. * Changes from baseline to week 8 in HAM-A total scores Changes from baseline to week 8 ...

Eligibility Criteria

Inclusion

  • Patients with a DSM IV diagnosis of major depression and fibromyalgia confirmed by using the American College of Rheumatology criteria. Male or female between the ages of 18 and 65.
  • Patients who score at least 22 on the 17-item HAM-D scale and at least 4 (i.e., moderately ill) on the Clinical Global Impression (CGI) severity scale. Both criteria have to be met at screening and baseline (Study Day 0).

Exclusion

  • Patients with DSM-IV Axis 1 disorder other than MDD and Chronic Pain Disorder within 6 months of enrolment.
  • History of inadequate response to adequate treatment (6 weeks) with 2 or more classes of antidepressants during current depressive episode.
  • Patients who, in the investigator's opinion, pose a risk for suicide.
  • History of suicide attempt within 3 years of entering study.
  • Current depressive episode secondary to general medical condition excluding Fibromyalgia.
  • History or presence of bipolar disorder or psychosis.
  • Post traumatic stress disorder, anorexia nervosa or bulimia nervosa.
  • Patients with diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status.
  • Present DSM IV diagnosis of substance abuse or dependence within 6 months prior of the screening visit (except dependence in full remission, and except caffeine, nicotine or opiate dependence)

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2011

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00675896

Start Date

April 1 2007

End Date

July 1 2011

Last Update

July 6 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dr. A McIntyre Inc

Penticton, British Columbia, Canada, V2A 4M4